Immunotherapy Programs
Cancer
Pre-clinicalActive
Key Facts
About CheckMab
CheckMab is a private, pre-revenue biotech firm leveraging monoclonal antibody technology for diagnostic and therapeutic applications in oncology and autoimmunity. Founded in 2006 and headquartered in Siena, Italy, the company appears to be in the pre-clinical or early development stage, focusing on translating its antibody expertise into novel tests and potential therapies. Its strategy involves partnerships to advance its programs, targeting significant unmet medical needs in cancer and autoimmune disease diagnostics.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |